Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.72 |
| ▸ | MEN1 | O00255 | 5/20 | 0.71 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.63 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | GFER | P55789 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5679866 | 0.98 | KMT2A (0.74) | KMT2AMEN1SIGMAR1KDM4EALDH1A1 | |
| SCHEMBL8594195 | 0.85 | KMT2A (0.58) | KMT2AMEN1SIGMAR1KDM4EALDH1A1 | |
| SCHEMBL30118954 | 0.85 | KMT2A (0.71) | KMT2AMEN1SIGMAR1KDM4EALDH1A1 | |
| SCHEMBL8328272 | 0.85 | KMT2A (0.67) | KMT2AMEN1SIGMAR1KDM4EALDH1A1 | |
| SCHEMBL3624308 | 0.85 | KMT2A (0.69) | KMT2AMEN1SIGMAR1KDM4EALDH1A1 | |
| SCHEMBL8325065 | 0.85 | KMT2A (0.71) | KMT2AMEN1SIGMAR1KDM4EALDH1A1 | |
| SCHEMBL3242055 | 0.84 | KMT2A (0.56) | KMT2AMEN1SIGMAR1KDM4EALDH1A1 | |
| SCHEMBL22813637 | 0.84 | KMT2A (0.69) | KMT2AMEN1SIGMAR1KDM4EALOX15 | |
| SCHEMBL2238597 | 0.81 | ALDH1A1 (0.60) | KMT2AMEN1KDM4EALDH1A1MAPT | |
| SCHEMBL17868771 | 0.81 | KMT2A (0.58) | KMT2AMEN1ALDH1A1TSHRSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9938415-B2 | Functionalised antifouling compounds and use thereof | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2018-04-10 | — | — | US | disclosed |
| US-20160009926-A1 | FUNCTIONALISED ANTIFOULING COMPOUNDS AND USE THEREOF | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2016-01-14 | — | — | US | disclosed |
| US-9169223-B2 | Functionalised antifouling compounds and use thereof | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2015-10-27 | — | — | US | disclosed |
| EP-2531494-A1 | FUNCTIONALISED ANTIFOULING COMPOUNDS AND USE THEREOF | Agency For Science, Technology And Research (SG) | 2012-12-12 | — | — | EP | disclosed |
| US-20120301423-A1 | FUNCTIONALISED ANTIFOULING COMPOUNDS AND USE THEREOF | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2012-11-29 | — | — | US | disclosed |
| WO-2011096897-A1 | FUNCTIONALISED ANTIFOULING COMPOUNDS AND USE THEREOF | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2011-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160009926-A1 | FUNCTIONALISED ANTIFOULING COMPOUNDS AND USE THEREOF | PFAS, ALKBH3, ITGA1 | KMT2A 1621/4885MEN1 4475/4885SIGMAR1 158/4885 |
| US-20120301423-A1 | FUNCTIONALISED ANTIFOULING COMPOUNDS AND USE THEREOF | PFAS, TST, EPCAM | KMT2A 1701/4885MEN1 4371/4885SIGMAR1 228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.